IMB update - thesis alignement review

IMB H1 FY 26

I think IMB remains an attractive investment opportunity given the recent decline in price.

The market might have been spooked by the slower recurring revenue growth base, and especially the decline in monitoring revenue.

But guidance has been maintained, and based on the previous 2 years, H2 has always been stronger than H1. Especially for the weaker New…